Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2002 1
2003 1
2005 1
2006 1
2007 3
2008 2
2009 1
2010 2
2011 2
2012 1
2013 1
2014 1
2015 1
2016 2
2017 2
2020 2
2021 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.
Cahn P, Sierra Madero J, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man CY, Urbaityte R, Brandon DJ, Underwood M, Pappa KA, Curtis L, Smith KY, Gartland M, Aboud M, van Wyk J, Wynne B. Cahn P, et al. Among authors: man cy. AIDS. 2022 Jan 1;36(1):39-48. doi: 10.1097/QAD.0000000000003070. AIDS. 2022. PMID: 34534138 Free PMC article. Clinical Trial.
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man CY, Urbaityte R, Brandon DJ, Underwood M, Tenorio AR, Pappa KA, Wynne B, Gartland M, Aboud M, van Wyk J, Smith KY. Cahn P, et al. Among authors: man cy. J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):310-318. doi: 10.1097/QAI.0000000000002275. J Acquir Immune Defic Syndr. 2020. PMID: 31834000 Free PMC article. Clinical Trial.
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
Eron J, Hung CC, Baril JG, Slim J, Falcó V, Bogner J, Maggiolo F, Mills A, Sievers J, Man CY, Urbaityte R, Underwood M, Tenorio AR, Pappa KA, Wynne B, Koteff J, Gartland M, Smith KY, Aboud M. Eron J, et al. Among authors: man cy. J Acquir Immune Defic Syndr. 2020 May 1;84(1):60-65. doi: 10.1097/QAI.0000000000002302. J Acquir Immune Defic Syndr. 2020. PMID: 31977595 Clinical Trial.
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man CY, Aylott A, Buchanan AM, Wynne B, Vavro C, Aboud M, Smith KY; ARIA study team. Orrell C, et al. Among authors: man cy. Lancet HIV. 2017 Dec;4(12):e536-e546. doi: 10.1016/S2352-3018(17)30095-4. Epub 2017 Jul 17. Lancet HIV. 2017. PMID: 28729158 Clinical Trial.
28 results